Your session is about to expire
← Back to Search
NAP + Docetaxel for Lung Cancer (NT-NAP-102-1 Trial)
NT-NAP-102-1 Trial Summary
This trial is testing a new cancer drug, NAP, to see if it is effective when used with the existing drug docetaxel. The trial will involve pretreating patients with obinutuzumab (another existing drug) before giving them the NAP/docetaxel combination. Treatment cycles will last 21 days.
NT-NAP-102-1 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowNT-NAP-102-1 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.NT-NAP-102-1 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I had brain metastases treated and am stable without needing high-dose steroids.I've had 1-2 treatments for advanced lung cancer and my cancer grew despite these treatments.I have not needed treatment for an infection within 3 days of starting the trial.I am 18 years old or older.I am fully active or restricted in physically strenuous activity but can do light work.My lung cancer diagnosis was confirmed through lab tests.I am currently receiving treatment for another cancer.My disease is advanced and cannot be cured.You must have a measurable cancer that can be seen and measured using specific guidelines.I have or had an autoimmune or inflammatory disorder, but not vitiligo, psoriasis without recent treatment, stable endocrinopathies, primary immunodeficiency, or a history of organ transplant.
- Group 1: NAP in combination with docetaxel following obinutuzumab pretreatment
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How widely distributed is this experiment across the United States?
"Participants for this medical trial may be enrolled at NeoTX- 10200 in Hartford, Connecticut, NeoTX - 10307 in Daphne, Alabama and NeoTX - 10100 in Morristown, New jersey or any of the additional 13 sites."
What medical conditions are managed with NAP (Naptumomab estafenatox)?
"Naptumomab estafenatox (NAP) is utilized to treat malignant neoplasms, as well as advance directives, sarcoma, and refractory follicular lymphoma."
Are there currently any open recruitment opportunities for this trial?
"According to clinicaltrials.gov, this research project is actively seeking participants and began advertising on October 26th 2021. The most recent update was logged August 25th 2022."
What potential adverse effects could arise from NAP (Naptumomab estafenatox) treatment?
"There is some evidence that NAP (Naptumomab estafenatox) can be considered a safe medication, so it received an evaluation score of 2. This reflects the Phase 2 nature of this trial as there is data for safety but not yet efficacy."
What is the total number of participants enrolled in this research project?
"This clinical trial necessitates 35 individuals that fulfill the criteria for enrolment. Eligible participants may enrol from NeoTX- 10200 in Hartford, Connecticut or NeoTX - 10307 in Daphne, Alabama."
Have any further investigations been conducted using the drug NAP (Naptumomab estafenatox)?
"Currently, 419 separate studies centred around NAP (Naptumomab estafenatox) are happening in the world with 144 of these trials at Phase 3. There is a concentration of clinical studies taking place in Fuzhou, Fujian yet 27228 distinct locations have active research projects focusing on this drug."
Share this study with friends
Copy Link
Messenger